Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Joseph Panoff

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Transplantation and Cellular Therapy
Volume	27
State	Published - Jun 1 2021

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{379a72493d66489d94d76aedb8774be1,

title = "Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1",

author = "Joseph Panoff",

note = "Transplant Cell Ther (2021) 27(6).",

year = "2021",

month = jun,

day = "1",

language = "American English",

volume = "27",

journal = "Transplantation and Cellular Therapy",

}

TY - JOUR

T1 - Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

AU - Panoff, Joseph

N1 - Transplant Cell Ther (2021) 27(6).

PY - 2021/6/1

Y1 - 2021/6/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3895

M3 - Article

VL - 27

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

ER -

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1

Access to Document

Other files and links

Cite this